US Tariffs Won’t Derail Plans For Antibiotic Zaynich: Dr Habil F Khorakiwala

In this exclusive conversation, Sakshi Batra speaks with Dr. Habil Khorakiwala, Founder Chairman of Wockhardt Group, as the company prepares to file an application for its new drug Zaynich with the USFDA next week. However, the recent imposition of 100% tariffs on certain pharma imports has created new challenges. Dr. Khorakiwala confirms that Wockhardt is not currently manufacturing in the US, but the company is exploring alternative strategies — including licensing agreements and contract manufacturing within the US — to sidestep tariff barriers without setting up a new facility. He also sheds light on the broader landscape: while Indian pharmaceutical companies dominate the generics space in the US, very few export branded drugs. Despite trade obstacles, the US remains the largest export market for Indian pharma, and Wockhardt is determined to maintain a strong presence. Additionally, Wockhardt plans to expand Zaynich into Europe and other global (ROW) markets, reinforcing its commitment to international growth. “We will find a solution,” says Dr. Khorakiwala, confidently outlining a future where strategic flexibility is key to overcoming global hurdles. Don’t miss this candid and insightful discussion on the future of Indian pharma and Wockhardt’s vision for global healthcare.